- Home
- CELU vs BTAI Comparison
CELU vs BTAI Comparison
Compare CELU & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- BTAI
- Stock Information
- Founded
- CELU 2016
- BTAI 2017
- Country
- CELU United States
- BTAI United States
- Employees
- CELU N/A
- BTAI N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- BTAI Health Care
- Exchange
- CELU Nasdaq
- BTAI Nasdaq
- Market Cap
- CELU 56.9M
- BTAI 48.3M
- IPO Year
- CELU N/A
- BTAI 2018
- Fundamental
- Price
- CELU $1.74
- BTAI $1.93
- Analyst Decision
- CELU Strong Buy
- BTAI Buy
- Analyst Count
- CELU 1
- BTAI 5
- Target Price
- CELU $6.00
- BTAI $32.80
- AVG Volume (30 Days)
- CELU 153.9K
- BTAI 930.7K
- Earning Date
- CELU 12-05-2025
- BTAI 11-12-2025
- Dividend Yield
- CELU N/A
- BTAI N/A
- EPS Growth
- CELU N/A
- BTAI N/A
- EPS
- CELU N/A
- BTAI N/A
- Revenue
- CELU $44,590,000.00
- BTAI $868,000.00
- Revenue This Year
- CELU N/A
- BTAI N/A
- Revenue Next Year
- CELU $76.00
- BTAI $544.99
- P/E Ratio
- CELU N/A
- BTAI N/A
- Revenue Growth
- CELU 4.45
- BTAI N/A
- 52 Week Low
- CELU $1.00
- BTAI $1.17
- 52 Week High
- CELU $5.22
- BTAI $12.16
- Technical
- Relative Strength Index (RSI)
- CELU 34.57
- BTAI 33.35
- Support Level
- CELU $1.62
- BTAI $2.14
- Resistance Level
- CELU $1.99
- BTAI $2.46
- Average True Range (ATR)
- CELU 0.11
- BTAI 0.14
- MACD
- CELU -0.02
- BTAI -0.01
- Stochastic Oscillator
- CELU 21.15
- BTAI 13.85
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.